FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1639-1641 December 14, 1995 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Singh, S. N. PubMed Citation

To the Editor: It is important to clarify the role of amiodarone in patients with congestive heart failure, and the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure reported by Singh and colleagues (July 13 issue)¹ advances the field. However, we would like to register some key reservations about that study.

First, there was a 27 percent rate of discontinuation of the study drug in the amiodarone group (vs. 23 percent in the placebo group), and an additional 14 percent of patients (vs. 9 percent in the placebo group) were lost to follow-up or withdrew from the study. Thus, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.